The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Petrova N.N.

Saint-Petersburg State University

The problem of suicide in depression in the modern world

Authors:

Petrova N.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(6‑2): 43‑48

DOI: 10.17116/jnevro202212206243

Views: 5279

Downloaded: 122

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Petrova NN. The problem of suicide in depression in the modern world. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(6‑2):43‑48. (In Russ.)
https://doi.org/10.17116/jnevro202212206243

 
МСФ на ЯМ
Close metadata
Recommended articles:
The effect of inso­mnia on mild cognitive impairment in patients with vascular risks: resu­lts of a three-year longitudinal study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):30-36
Sleep diso­rders and onco­logical diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):125-131
A perspective on the application of CRISPR/CAS9 genome editing system to study of mole­cular-genetic basis of mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):27-33
Vali­dation of screening method based on EEG analysis for the risk asse­ssment of psychiatric and beha­vioral diso­rders: a pilot study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):88-96
A clinical case of the new-onset bipo­lar affe­ctive diso­rder in the postcovid period. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):125-129
Pathogenetic basis of modern approaches to the therapy of sleep diso­rders in the clinic of depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):69-74
Features of the clinical picture of affe­ctive diso­rders in women during the meno­pausal transition and early postmenopause. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):75-79
Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):22-30
Asthenia in young patients and possibilities for its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):133-137
Pharmacogenomic and pharmacometabolomic biomarkers of the effi­cacy and safety of anti­depressants: focus on sele­ctive sero­tonin reuptake inhi­bitors. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):26-35

OBJECIVE

To analyze the literature data on the relationship between antidepressant therapy and suicide risk and the ways to prevent suicidal behavior in patients on antidepressant therapy.

MATERIAL AND METHODS

A non-systematic review of publications was conducted using keywords in the following databases: ELibrary.ru, PubMed, Cochrane Database of Systematic Reviews. Inclusion criteria were meta-analyses, Cochrane reviews, epidemiological and original studies.

RESULTS

Data from original studies are inconsistent, but more evidence-based epidemiologic studies support the preventive role of antidepressant therapy with regard to suicide. An increased risk of suicide with antidepressant therapy is seen in younger patients, especially in the first 2 weeks of treatment, in the absence of a therapeutic response. The initial dosage of antidepressants, possibly the type of antidepressant, is of some importance. The group at risk of committing suicide is those who have received psychotropic therapy in the previous year.

CONCLUSION

There is no generally accepted model of prevention, but it is recommended that patients be observed during the first 4 weeks of treatment for depression, as well as during the period of antidepressant dose modification.

Keywords:

depression
antidepressants
suicide risk

Authors:

Petrova N.N.

Saint-Petersburg State University

Received:

05.04.2021

Accepted:

14.09.2021

List of references:

  1. Liu Q, He H, Yang J, et al. Changes in the global burden of depression from 1990 to 2017: Findings from the Global Burden of Disease study. J Psychiatric Res. 2020;126:134-140. 
  2. Conejero I, Olié E, Calati R et al. Psychological Pain, Depression, and Suicide: Recent Evidences and Future Directions. Curr Psychiatry Rep. 2018;20(5):33.  https://doi.org/10.1007/s11920-018-0893-z
  3. WHO. Preventing Suicide: A global imperative. Geneva: World Health Organization; 2014.
  4. Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-COVID syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693.
  5. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bi-directional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. The lancet Psychiatry. 2020;S2215-0366;20:30462-4. 
  6. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601-615. 
  7. Wong AW, Shah AS, Johnston JC, et al. Patient-reported outcome measures after COVID-19: a prospective cohort study. Eur Respir J. 2020;56(5):2003276. https://doi.org/10.1183/13993003.03276-2020
  8. Morin L, Savale L, et al. Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. JAMA. 2021;325:1525(15):1525-1534. https://doi.org/10.1001/jama.2021.3331
  9. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-232.  https://doi.org/10.1016/S0140-6736(20)32656-8
  10. Guo Q, Zheng Y, Shi J, et al. Immediate psychological distress in quarantined patients with COVID-19 and its association with peripheral inflammation: a mixed-method study. Brain Behav Immun. 2020;88:17-27.  https://doi.org/10.1016/j.bbi.2020.05.038
  11. Pierce M, Hope H, Ford T et al. Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK population. Lancet Psychiatry. 2020;7:883-892. 
  12. Shader RI. COVID-19 and depression. Clin Therapeutics. 2020;42(6):962-963. 
  13. Panchal N, Kamal R, Cox C, Garfield R. The Implications of COVID-19 for Mental Health and Substance Use, KFF. 2020.
  14. National Child Mortality Database. Child suicide rates during the covid-19 pandemic in England: real-time surveillance. 2020. https://www.ncmd.info/wp-content/uploads/2020/07/REF253-2020-NCMD-Summary-Report-on-Child-Suicide-July-2020.pdf
  15. Ueda M, Nordstrӧm R, Matsubayashi T. Suicide and mental health during the COVID-19 pandemic in Japan. med Rxiv. 2020 [Preprint]. https://doi.org/10.1101/2020.10.06.20207530
  16. Faust J, Shah S, Du C, et al. Suicide deaths during the stay-at-home advisory in Massachusetts. medRxiv. 2020. https://doi.org/10.1101/2020.10.20.20215343
  17. Pokhrel S, Sedhai YR, Atreya A. An increase in suicides amidst the coronavirus disease 2019 pandemic in Nepal. Med Sci Law. 2020;25802420966501. pmid: 33036544. https://doi.org/10.1177/0025802420966501
  18. Czeisler ME, Lane RI, Petrosky E, et al. Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24—30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1049-1057. https://doi.org/10.15585/mmwr.mm6932a1
  19. Reger MA, Stanley IH, Joiner TE. Suicide Mortality and Coronavirus Disease 2019-A Perfect Storm? JAMA Psychiatry. 2020;77(11):1093-1094. https://doi.org/10.1001/jamapsychiatry.2020.1060
  20. Qin P, Mehlum L. National observation of death by suicide in the first 3 months under COVID-19 pandemic. Acta Psychiatr Scand. 2020. pmid: 33111325.
  21. Niederkrotenthaler T, Voracek M, Herberth A, et al. Role of media reports in completed and prevented suicide: Werther v. Papageno effects. Br J Psychiatry. 2010;197:234-243. pmid: 20807970. https://doi.org/10.1192/bjp.bp.109.074633
  22. Hawton K, Marzano L, Fraser L, et al. Reporting on suicidal behaviour and covid-19 — need for caution. Lancet Psychiatry. 2021;8(1):15-17.  https://doi.org/10.1016/S2215-0366(20)30484-3
  23. Wang SM, Han C, Bahk WM et al. Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review. Chonnam Med J. 2018;54(2):101-112. 
  24. Braun C, Bschor T, Franklin J, Baethge Ch. Suicides and Suicide Attempts during Long-Term Treatment with Antidepressants: A Meta-Analysis of 29 Placebo-Controlled Studies Including 6,934 Patients with Major Depressive Disorder Psychother Psychosom. 2016;85(3):171-179. Epub 2016 Apr 5.  https://doi.org/10.1159/000442293
  25. Brent DA. Antidepressants and Suicidality. Psychiatr Clin N Am. 2016;39:503-512.  https://doi.org/10.1016/j.psc.2016.04.002
  26. Hatzinger M. Antidepressants and Suicidality: A Contradiction? Praxis (Bern 1994). 2019;108(7):487-494.  https://doi.org/10.1024/1661-8157/a003235
  27. Isacsson G, Rich C. Antidepressant medication prevents suicide: a review of ecological studies. Eur Psychiaty Rev. 2008;1:24-26. 
  28. Stene-Larsen K, Reneflot A. Contact with primary and mental health care prior to suicide: A systematic review of the literature from 2000 to 2017. Scandinavian Journal of Public Health. 2019;47(1):9-17.  https://doi.org/10.1177/1403494817746274
  29. Windfuhr K, While D, Kapur N, et al. Suicide risk linked with clinical consultation frequency, psychiatric diagnoses and psychotropic medication prescribing in a national study of primary-care patients. Psychol Med. 2016;46(16):3407-3417. https://doi.org/10.1017/S0033291716001823
  30. Gorton HC, Webb RT, Kapur N, et al. Non-psychotropic medication and risk of suicide or attempted suicide: a systematic review. BMJ Open. 2016;6(1):e009074. https://doi.org/10.1136/bmjopen-2015-009074
  31. Benson T, Corry C, O’Neill S, et al. Use of prescription medication by individuals who died by suicide in Northern Ireland. Archives of Suicide Research. 2018;22(1):139-152.  https://doi.org/10.1080/13811118.2017.1289870
  32. Reneflot A, Kaspersen SL, Hauge LJ, Kalseth J. Use of prescription medication prior to suicide in Norway. BMC Health Services Research. 2019;19:215.  https://doi.org/10.1186/s12913-019-4009-1
  33. Henriksson S, Boëthius G, Isacsson G. Suicides are seldom prescribed antidepressants: findings from a prospective prescription database in Jämtland county, Sweden, 1985—95. Acta Psychiatr Scand. 2001;103(4):301-306.  https://doi.org/10.1034/j.1600-0447.2001.00276.x
  34. Courtet P, Nobile B, Lopez-Castroman J. Antidepressants and suicide risk — harmful of useful? In: Kumar U (ed). Handbook of suicidal behaviour. Bangalore: Springer Nature; 2017;329-347. 
  35. Hayes JF, Lewis G, Lewis G. Newer-Generation Antidepressants and Suicide Risk. Psychother Psychosom. 2019;88:371-372. 
  36. Wichniak A, Wierzbicka A, Jernajczyk W. Sleep and antidepressant treatment. Curr Pharm Des. 2012;18(36):5802-5817.
  37. Pigeon WR, Pinquart M, Conner K. Meta-analysis of sleep disturbance and suicidal thoughts and behaviors. J Clin Psychiatry. 2012;73(9):e1160-1167.
  38. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ. 2005;330:385.  https://doi.org/10.1136/bmj.330.7488.385
  39. Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ. 2005;330:396.  https://doi.org/10.1136/bmj.330.7488.396
  40. Buckley NA, McManus PR. Fatal toxicity of serotonergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ. 2002;325:1332-1333. https://doi.org/10.1136/bmj.325.7376.1332
  41. Rose JC, Unis AS. A mortality index for postmarketing surveillance of new medications. Am J Emerg Med. 2000;18:176-179. 
  42. White NC, Litovitz T, Clancy C. Suicidal antidepressant overdoses: A comparative analysis by antidepressant type. J Med Toxicol. 2008;4(4):238-250.  https://doi.org/10.1007/BF03161207
  43. Kasimova LN, Svyatogor MV, Vtyurina MV. Analysis of suicide attempts by self-poisoning. Suicidology. 2011;1:54-55. (In Russ.).
  44. Sharma T, Schow Guski L, Freund N, Gøtzsche PC Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ. 2016;352:i65. Published online 2016 Jan 27. PMCID: PMC4729837. PMID: 26819231. https://doi.org/10.1136/bmj.i65
  45. Khan A, Fahl Mar K, Gokul S, Brown WA. Decreased suicide rates in recent antidepressant clinical trials. Psychopharmacology (Berl). 2018;235(5):1455-1462.
  46. Hengartner M, Plöderl M. Newer-Generation Antidepressants and Suicide Risk in Randomized Controlled Trials: A Re-Analysis of the FDA Database. Psychother Psychosom. 2019;88(4):247-248.  https://doi.org/10.1159/000501215
  47. Kaminskia JA, Bschor T. Antidepressants and suicidality: A re-analysis of the re-analysis. Journal of Affective Disorders. 2020;266:95-99. 
  48. Choi KW, Kim YK, Jeon HJ. Comorbid Anxiety and Depression: Clinical and Conceptual Consideration and Transdiagnostic Treatment. Adv Exp Med Biol. 2020;1191:219-235.  https://doi.org/10.1007/978-981-32-9705-0_14
  49. Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342-351. 
  50. Domschke K, Deckert J, Arolt V, Baune BT. Anxious versus non-anxious depression: difference in treatment outcome. J Psychopharmacol. 2010;24(4):621-622. 
  51. Shepard DS, Gurewich D, Lwin AK, et al. Suicide and suicidal attempts in the United States: costs and policy implications. Suicide Life Threat Behav. 2016;46(3):352-362.  https://doi.org/10.1111/sltb.12225
  52. Oquendo MA, Bernanke JA. Suicide risk assessment: tools and challenges. World Psychiatry. 2017;16(1):28-30. 
  53. Courtet P, Lopez-Castroman J. Antidepressants and suicide risk in depression. World Psychiatry. 2017;16(3):317-318.  https://doi.org/10.1002/wps.20460
  54. Gupta S, Gersing KR, Erkanli A, Burt T. Antidepressant Regulatory Warnings, Prescription Patterns, Suicidality and Other Aggressive Behaviors in Major Depressive Disorder and Anxiety Disorders. Psychiatr Q. 2016;87(2):329-342.  https://doi.org/10.1007/s11126-015-9389-8
  55. National Collaborating Centre for Mental Health (UK). Depression: the treatment and management of depression in adults. Leicester (UK): British Psychological Society;2020. https://www.nice.org.uk/SG90
  56. Brent DA, Emslie GJ, Clarke GN, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry. 2009;166(4):418-426. 
  57. American Academy of Child & Adolescent Psychiatry. Information for patients and their families. https://www.aacap.org/AACAP/Resources_for_Primary_Care/Information_for_Patients_and_Their_Families/Home.aspx?hkey5bce12396-b276-4fed-8430-ca8628eb1a2b.
  58. Courtet P, Lopez-Castroman J, Jaussent I, et al. Antidepressant dosage and suicidal ideation. JAMA Intern Med. 2014;174(11):1863-1865.
  59. Coupland C, Hill T, Morriss R, et al. Antidepressant use and risk of suicide and attempted suicide or self-harm in people aged 20 to 64: cohort study using a primary care database. BMJ. 2015;350:h517.
  60. Nischal A, Tripathi A, Trivedi JK. Suicide and Antidepressants: What Current Evidence Indicates Mens Sana Monogr. 2012;10(1):33-44.  https://doi.org/10.4103/0973-1229.87287
  61. Healey D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom. 2003;72(2):71-79.  https://doi.org/10.1159/000068691
  62. NICE Preventing suicide. 2018, 2019.
  63. Tsukarzi EE. Suicide: risk assessment and first aid. Modern Therapy of Mental Disorders. 2011;2:30-40. (In Russ.).
  64. Courtet Ph, Lopez-Castroman J. Antidepressants and suicide risk in depression. World Psychiatry. 2017;16(3):317-318. 
  65. Ryan EP, Maria A. Oquendo Suicide Risk Assessment and Prevention: Challenges and Opportunities. Focus (Am Psychiatr Publ). 2020;18(2):88-99. Epub 2020 Apr 23.  https://doi.org/10.1176/appi.focus.20200011

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.